Can a Mucus-Thinning drug also fight inflammation in COPD?

NCT ID NCT07329946

Not yet recruiting Disease control Sponsor: Pierachille Santus, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will test whether the drug erdosteine, added to standard COPD treatment, can reduce inflammation and oxidative stress in the body. Thirty adults with moderate-to-severe COPD will take either erdosteine or their usual inhaled therapy for 30 days. Researchers will analyze blood samples to see how the drug affects immune and stress-related pathways, aiming to understand why it may reduce flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Erdosteine (a mucolytic drug with antioxidant and anti-inflammatory properties)
What this could lead to: If successful, this study could explain how erdosteine helps reduce COPD flare-ups and improve quality of life, potentially leading to better management strategies.
What could go wrong: This is a very small, early-stage exploratory study (30 people) that looks at biological markers, not clinical outcomes. Results may not translate to real-world benefits or be generalizable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

L. Sacco Hospital

Milan, 20157, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.